About

I am a board-certified urologist and surgeon-scientist with >50 peer-reviewed publications, currently serving as Interim Chief of Urology and Director of Urology Research at Endeavor Health, and as a Clinical Associate Professor at the University of Chicago Pritzker School of Medicine.

My primary subspecialty focus is benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). I currently lead two active NIH R01 grants totaling over $6 million in funding to investigate the inflammatory drivers of BPH and to enhance clinical decision-making through high-resolution patient-reported outcomes (PROs). I am also a member of the NIH Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN).

My educational background includes undergraduate studies in Molecular Biology at Colgate University, followed by my M.D., urologic surgical training, and an Immuno-Oncology Research Fellowship at Northwestern University. In addition to BPH, I specialize in endourology, kidney stone prevention and managemnet, and the diagnosis and treatment of prostate cancer, with a focus on novel image-guided focal therapies designed to minimize treatment side effects.

Beyond my clinical and research roles, I am a consultant, proctor, and key opinion leader for advanced minimally invasive technologies, including image-guided tissue ablation. My background is uniquely informed by formal business training from Harvard Business School and the Kellogg School of Management, which I apply as a medical advisor for health-tech startups specializing in remote diagnostics and agentic AI. Nationally, I hold leadership positions as a Education Committee Co-Chair for the Society of Benign Prostate Disease (SoBPD) and serve as a peer reviewer for the NIH and the AUA BPH Guidelines.

A dedicated surgeon-scientist by day, I recharge by running, skiing, hiking, and traveling with my wife and kids.